Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glucagon + exendin9-39
- Development stage
- Phase 1
- Lead developer
- Bispebjerg and Frederiksberg Hospital
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
Glucagon + exendin9-39 is a research-stage combination intervention consisting of the peptide hormone glucagon and the GLP-1 receptor (GLP-1R) antagonist exendin9-39. This combination is primarily used as a pharmacological tool in mechanistic clinical studies to investigate the physiological effects of glucagon on renal hemodynamics. Glucagon is known to influence renal blood flow and electrolyte balance, but because it can also cross-activate the GLP-1 receptor, exendin9-39 is co-administered to selectively block GLP-1R signaling. This allows researchers to isolate the effects mediated specifically through the glucagon receptor. The combination has been studied by Bispebjerg Hospital in healthy volunteers to map regional blood flow in the kidney cortex and medulla using MRI.
- Other names
- glucagon + exendin 9-39
02
Targets
GCGR (Glucagon receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on glucagon + exendin9-39.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glucagon + exendin9-39.